B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches is a paper indexed in ScholarIQ from OpenAlex.
How many citations does B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches have?
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches has 501 citations in the OpenAlex counts ScholarIQ stores.
When was B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches published?
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches has 2020 year in the ScholarIQ index.
What is the open-access status of B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches?
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches has hybrid oa status in the ScholarIQ index.
What is the DOI of B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches?
The DOI for B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches is on the source record.
What is the PMID of B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches?
The PMID for B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches is on the source record.
What is the OpenAlex record for B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches?
The OpenAlex for B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches is on the source record.